The 9th RNA-Targeted Drug Discovery & Development Summit brings together the leaders advancing RNA-targeted small molecules from early discovery through clinical development. Join senior decision-makers, technical experts, and scientific innovators from biotech, pharma, and academia to uncover the latest advances in RNA-targeted therapeutics.
Large Pharma & Strategic Partners
For organizations evaluating RNA-targeted small molecules as the next therapeutic modality.
Key companies include: AstraZeneca, Sanofi, Pfizer, Novartis, Eli Lilly, Astellas, Chugai, Daiichi Sankyo.
Biotech Executives, Founders & CSOs
Join the executive leaders accelerating the next generation of RNA-targeted therapeutics and discover where the field is headed next.
Key companies include: Remix Therapeutics, PTC Therapeutics, ReviR Therapeutics, Sanofi, Pfizer, Ribonaut Therapeutics, Atomic AI, Dewpoint Therapeutics, EPICS Therapeutics, AstraZeneca, Ribometrix, Arrakis Therapeutics.
Biotech Drug Developers
For companies building RNA-targeted small molecule platforms and pipelines.
Key companies include: Remix Therapeutics, ReviR Therapeutics, Arrakis Therapeutics, Ribometrix, Ribonaut Therapeutics, Dewpoint Therapeutics, Syrna Therapeutics, Renasis Bio, RevoNA Bio.
Discovery & Translational Scientists
For technical experts developing the next generation of RNA-targeted therapeutics.
Key functions include: RNA Biology, Medicinal Chemistry, Drug Discovery, Screening, Structural Biology, Computational Biology, and Translational Sciences.
Academic & Research Pioneers
For researchers advancing understanding of RNA structure, biology and druggability.
Institutions include: UNC Chapel Hill, University of Toronto, University of Colorado Boulder, University of Wisconsin–Madison and many more.